Intuitive Surgical (NASDAQ:ISRG) Given Overweight Rating at Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of Intuitive Surgical (NASDAQ:ISRG) in a research note released on Friday,Benzinga reports. Piper Sandler currently has a $670.00 price target on the medical equipment provider’s stock, up from their previous price target of $538.00.

Several other equities analysts have also weighed in on ISRG. Truist Financial lifted their target price on shares of Intuitive Surgical from $570.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Wells Fargo & Company boosted their target price on shares of Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a research report on Friday. Oppenheimer reissued a “market perform” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. Leerink Partners increased their price target on Intuitive Surgical from $489.00 to $502.00 in a report on Thursday, October 17th. Finally, BTIG Research lifted their price target on shares of Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $583.83.

Intuitive Surgical Trading Down 4.0 %

ISRG stock opened at $584.05 on Friday. Intuitive Surgical has a 12-month low of $364.17 and a 12-month high of $616.00. The company has a market cap of $208.03 billion, a PE ratio of 93.90, a price-to-earnings-growth ratio of 5.19 and a beta of 1.39. The stock has a 50-day moving average price of $546.03 and a two-hundred day moving average price of $503.38.

Insider Buying and Selling

In other news, CEO Gary S. Guthart sold 18,151 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the transaction, the chief executive officer now directly owns 24,219 shares of the company’s stock, valued at approximately $12,391,166.97. This trade represents a 42.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jamie Samath sold 22,903 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $525.00, for a total transaction of $12,024,075.00. Following the completion of the transaction, the insider now owns 8,757 shares of the company’s stock, valued at $4,597,425. This represents a 72.34 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 42,475 shares of company stock valued at $22,070,807 in the last quarter. Company insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Intuitive Surgical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ISRG. Berbice Capital Management LLC bought a new position in shares of Intuitive Surgical in the fourth quarter valued at $26,000. Godsey & Gibb Inc. grew its position in Intuitive Surgical by 140.0% during the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 35 shares in the last quarter. MidAtlantic Capital Management Inc. acquired a new stake in shares of Intuitive Surgical in the third quarter worth $33,000. Decker Retirement Planning Inc. purchased a new stake in Intuitive Surgical in the 4th quarter worth about $36,000. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Intuitive Surgical in the third quarter worth approximately $38,000. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.